Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Indonesian Journal of Cancer
Lyana Setiawan
Department of Neurology, Dharma Jaya Hospital, Jalarta
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Immunophenotyping in the Diagnosis and Classification of Acute Leukemia: "Dharmais" Cancer Hospital Experience Kosasih, Agus Susanto; Setiawan, Lyana; Hartini, Sri
Indonesian Journal of Cancer Vol 5, No 1 (2011): Jan - Mar 2011
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (74.918 KB)

Abstract

Penentuan imunofenotipe merupakan salah satu pemeriksaan yang disyaratkan dalam diagnosis dan klasifikasi leukemia. Dalam tulisan ini, kami melaporkan data peranan penentuan imunofenotipe dalam diagnosis leukemia akut dikaitkan dengan pemeriksaan sitomorfologi dan pemeriksaan sitokimia Sudan Black B (SBB) yang dilakukan di Laboratorium Patologi Klinik Rumah Sakit Kanker “Dharmais” (RSKD) sejak Januari 2005 sampai Desember 2007.Menurut imunofenotipe, kami menemukan 13 kasus leukemia limfoblastik akut (LLA) galur T, 82 kasus LLA galur B, dan 110 kasus leukemia mieloblastik akut (LMA). Ko-ekspresi antigen dari galur lain ditemukan pada 38% kasus LLA-T, 28% kasus LLA-B, dan 37% LMA. Antigen limfoid yang paling sering ditemukan ekspresinya pada LMA adalah CD19 diikuti CD7.CD33 ditemukan pada 94,6% kasus LMA dan CD13 pada 87,8% kasus LMA. CD19 ditemukan pada 96% LLA-B, CD10 pada 68% kasus, diikuti CD20 (50%) dan CD22 (33%). CD7 ditemukan pada 92% LLA-T, dan CD3 positif pada 85% kasus LLA-T.Disimpulkan bahwa penentuan imunofenotipe sangat bermanfaat dalam penentuan diagnosis galur, membedakan antara LLA dan LMA, khususnya pada kasus dengan SBB negatif seperti pada kasus LMA-M0 dan M5a, membedakan LLA-B dan LLA-T, serta mendiagnosis kasus leukemia bifenotipe/leukemia galur campuran.Kata kunci: Leukemia akut, imunofenotipe, galur myeloid, LLA-B, LLA-T.
The Difference between Chronic Myeloid Leukemia before and during the COVID-19 Pandemic: A Retrospective Study from Dharmais Cancer Center Tadjoedin, Hilman; Suryana, Kresna Dharma; Hadisantoso, Dwi Wahyunianto; Siregar, Nia Novianti; Djamal, Rizky Syawaluddin; Setiawan, Lyana; Hartono, Bryan Arista; Kunigara, Manika Putri
Indonesian Journal of Cancer Vol 19, No 4 (2025): December
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i4.1365

Abstract

Background: Chronic myeloid leukemia (CML) is a rare disease, with a global incidence rate ranging from 10 to 15 cases per 1,000,000 population annually, constituting approximately 15% of all adult leukemia. The achievement of complete response in CML patients has been affected by the COVID-19 pandemic. This study aimed to determine differences in characteristics, survival, and complete hematological response (CHR) in CML patients before and after the COVID-19 pandemic at Dharmais Cancer Hospital.Method: A cohort retrospective was conducted using medical records among CML patients diagnosed and treated in 2018 to 2022 in Dharmais Cancer Hospital. Demographic, characteristics, and survival were described. Overall survival was analyzed using Kaplan-Meier and log-rank test, and bivariate analysis was used with the Chi-square and Fisher's exact test. Patients aged 18 years with CML confirmed by bone marrow analysis, and detected fusion of BCR-ABL were included, and multiple malignancies were excluded.Results: The study was conducted on 108 subjects (56 vs. 52, before and during the pandemic, respectively). The demographic characteristics in both periods showed that the majority of subjects were male (59.8% vs. 40.2%), had normal BMI (58.1% vs 41.9%), and had no comorbidities. However, there was a difference in age distribution. The subjects before the pandemic were predominantly over 40 years, while those during the pandemic were 18-39 years. A total of 91/108 subjects survived (49.5% before vs. 50.5% during the pandemic). The median overall survival was 55 vs. 52 months, with a p-value of 0.173. No significant association was found between the study period or history of COVID-19 infection and CHR. However, a significant association was observed between the CML phase and outcomes.Conclusion: No significant differences were observed in demographic or clinical characteristics, overall survival, or CHR among CML patients before and during the COVID-19 pandemic.
Co-Authors Agus Susanto Kosasih, Agus Susanto Djamal, Rizky Syawaluddin Hadisantoso, Dwi Wahyunianto Hartono, Bryan Arista HILMAN TADJOEDIN, HILMAN Kunigara, Manika Putri Lusy Erawati Maria Mayasari Muhammad U. Markum Nia Novianti Siregar, Nia Novianti Sri Hartini Suryana, Kresna Dharma